AstraZeneca drug selumetinib fails in uveal melanoma trial
July 22, 2015 at 02:27 AM EDT
LONDON, July 22 (Reuters) - AstraZeneca's much anticipated cancer drug pipeline suffered a blow on Wednesday when the experimental drug selumetinib failed to meet its goal in a late-stage trial for uveal melanoma.
